

DAFTAR PUSTAKA

1. Patel T, Chang F. Parkinson's disease guidelines for pharmacists. *Can Pharm J (Ott)*. 2014; 147(5): 161-70.
2. Tysnes O, Storstein A. Epidemiology of Parkinson's disease. *J Neural Transm*. 2017;124(8):901-5.
3. Kurniawan M, Suharjanti I, Pinzon RT. *Panduan Praktik Klinis Neurologi*. 2016. Jakarta: PERDOSSI.
4. Pinzon R, Adhayana K. *Penyakit Parkinson*. 2015. Betha Grafika, Yogyakarta hal 1-24.
5. Kassandra F. *Hubungan Antara Penggunaan Obat Anti Hipertensi dan Penyakit Parkinson di Rumah Sakit Bethesda Yogyakarta*; 2017.
6. Laksono SP, Qomariyah, Endang P. *Majalah Kesehatan PharmaMedika*, 2013;3(2): 268
7. Syamsudin, T. *Penyakit Parkinson*. Dalam: *Buku Panduan Tatalaksana Penyakit Parkinson dan Gangguan Gerak Lainnya*. Kelompok Studi Movement Disorder Perhimpunan Dokter Spesialis Saraf Indonesia (PERDOSSI). 2013
8. Sutia D. *Hubungan Kadar Alpha Synuclein Plasma dengan Penyakit Parkinson (Thesis)*. Padang: Universitas Andalas; 2014.
9. Dorsey ER, Bloem BR. The Parkinson pandemic - A call to action. *JAMA Neurol*. 2018;75(1):9-10
10. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: A systematic review and meta-analysis. *Mov Disord*, 2014;29(13):1583-90
11. Trisnadewi K. *Kadar asam urat serum rendah meningkatkan resiko penyakit Parkinson [Tesis]*. Denpasar: Program Studi Ilmu Biomedik (Program Pasca sarjana) Universitas Udayana; 2014.
12. Joesoef AA. *Parkinson's Disease : Basic Science dalam Parkinson's Disease & Other Movement Dissorder*, Pustaka Cendikia Press. 2007.
13. Margolius A, Cubillips F, He Y, Wu S, Schmidt P, Simuni T, on behalf of the NPF QII Investigators. Predictors of clinically meaningful change in PDQ-39 in Parkinson's disease. *J Parkinsonism and Related Disorders*. 2018.

14. Modestino EJ, Reinhofer AM, Blum K, Amenechi C, O'Toole P. Hoehn and Yahr staging of Parkinson's disease in relation to neurophysiological measures. *Front Biosci (Landmark Ed)*. 2018;23:1370-9
15. R. Bhidayasiri, D. Tarsy, *Movement Disorders: A Video Atlas*, Current Clinical Neurology, DOI 10.1007/978-1-60327-426-5_2. 2012.
16. Martinez-Martin P, Chaudhuri KR. Comprehensive grading of Parkinson's disease using motor and non-motor assessments: Addressing a key unmet need. *Expert Review of Neurotherapeutics*. 2018;1:41-50
17. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. *Lancet Neurol*. 2015;14:57-64
18. Carpi S, Carotenuto A, Colucci L, Ziello AR, Manzo V, Amenta ZF, Fasanaro AM. 2013. Non-motor symptoms in Parkinson's disease. *Current Neurobiology* 2013; 4 (1&2):53-65
19. World Health Organization (WHO). The World Health Organization Quality of Life Assessment (WHOQOL): Position paper from the World Health Organization. *Soc Sci Med*. 1995;4:1403-9.
20. Rubbyana, Urifah. Hubungan antara strategi coping dengan kualitas hidup pada pasien skizofrenia remisi simptom. *Jurnal Psikologi Klinis dan Kesehatan Mental*. 2012; 1:59-66.
21. Karangora MLB. Hubungan antara dukungan sosial dan kualitas hidup pada lesbian di Surabaya. *Jurnal Ilmiah Mahasiswa Universitas Surabaya*. 2012;8(1)
22. Martinez-Martin P. What is quality of life and how do we measure it? Relevance to Parkinson's disease and movement disorders. *Mov. Disord*. 2017;32:382-92.
23. Testa MA, Nackley JF. Methods for quality of life studies. *Annu. Rev. Public Health*. 1994;15:535-59.
24. Silitonga R. Faktor-faktor yang berhubungan dengan kualitas hidup penderita penyakit Parkinson di Poliklinik Saraf RS DR Kariadi [Tesis]. Semarang: Universitas Diponegoro; 2007.
25. World Health Organization (WHO). WHOQOL-BREF: Introduction, administration, scoring and generic version of the assesment: field trial

version. 1996.

26. Moreira, RC, Zonta MB, Araújo APS, Israel VL, Teive HAG . 2017. Quality of life in Parkinson's disease patients: progression markers of mild to moderate stages: *Arq Neuropsiquiatr* 2017;75(8):497-502
27. Schrag A, Jahanshahi m, Quinn N. What contributes to quality of life in patients with Parkinson's disease?. *J Neurol Neurosurg Psychiatry*. 2000;69:308-12
28. Karlsen KH, Larsen JP, Tandberg E, Maeland JG. Influence of clinical and demographic variables on quality of life in patients with Parkinson's Disease. *J Neurol Neurosurg Psychiatry*. 1999; 66: 431-35.
29. Karlsen KH, Larsen JP, Tandberg E, Arslan D. Health related quality of life in Parkinson's Disease: a prospective longitudinal study. *J Neurol Neurosurg Psychiatry*, 2000; 69: 584-9.
30. Souza RG, Borges V, Silva SM, Ferraz HB. Quality in life scale in Parkinson's disease PDQ-39 – (Brazilian Portuguese version) to assess patients with and without levodopa motor fluctuation. *Arq Neuropsiquiatr*. 2007;65(3-B):787-91.
31. Opara JA., Broła W, Leonardi M, Blaszczyk B. Quality of Life in Parkinson's Disease. *Journal of Medicine and Life*. 2012;5(4): 375-81.
32. Diniz, JG, Silva AC, Nobrega AC. Quality of life and swallowing questionnaire for individuals with Parkinson's disease: development and validation. *Int J Lang Commun Disord*. 2018;53(4):864-74
33. PERDOSSI. Standar Pelayanan Medik (SPM). 2011. Jakarta: PERDOSSI.
34. Tanto C, Liwang F, Hanidati S, Pradipta EA. Kapita selekta kedokteran. Edisi 4. Jakarta: Media Aesculapius; 2014. 971-3
35. Ascherio A, Schwarzschild MA. The epidemiology of parkinson's disease: risk factors and prevention. *Lancet Neurol*. 2016;15:1257–72.
36. Lumbantobing SM. Neurologi klinik: pemeriksaan fisik dan mental. Jakarta: Balai Penerbit FKUI. 2012; 89-95
37. Gunawan G, Dalhar M, Kurniawan SN. Review: Parkinson dan terapi stem sel. *MNJ*. 2017;3(1):39-46
38. Baehr MF, Michael. *Duus Topical Diagnosis in Neurology*. 4th ed. United

States of America: Thieme; 2005.

39. Price SA, Wilson LM, Hartwig MS. Gangguan neurologis dengan simptomatologi generalisata. Patofisiologi konsep klinis proses-proses penyakit Vol.2. Jakarta: EGC. 2006.
40. Sidharta P. Neurologi klinis dalam praktek umum. Jakarta: Dian Rakyat; 2008:370-71
41. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-76.
42. Harsono. Buku ajar neurologi klinis. Jogjakarta: Gadjah Mada University Press. 2008.
43. PERDOSSI. Buku ajar neurologi klinis. Yogyakarta: Gadjah Mada University Press. 2005; 233-44.
44. Kolegium Neurologi Indonesia. Modul neurologi. Jakarta: PERDOSSI. 2008
45. Uc EY, Tippin J, Chou KL, Erickson BA, Doerschug KC, Fletcher DMJ. Non-motor symptoms in parkinson's disease. US Neurology. 2011;7(2): 113-9.
46. Kano O, Ikeda K, Cridebring D, Takazawa T, Yoshii Y, Iwasaki Y. Neurobiology of depression and anxiety in parkinson's disease. SAGE-Hindawi Access to Research Parkinson's Disease. 2011; 13:1-5.
47. Bonnet AM, Jutras MF, Czer-necki V, Corvol JC, Vidailhet M. Nonmotor symptoms in parkinson's disease in 2012: relevant clinical aspects. parkinson's disease. 2012;1-15.
48. Dissanayaka NNW, Sellbach A, Matheson S, O'Sullivan JD, Silburn PA, Byrne GJ, et.al. Anxiety disorders in parkinson's disease: prevalence and risk factors. Movement Disorders. 2010;25(7):838-45.
49. John CM, Brust MD. Current Diagnosis & Treatment in Neurology. McGraw-Hill Professional. 2007.
50. Mabsusah. Kualitas hidup (quality of life) pasien diabetes mellitus di RSUD. DR. H. Slamet Martodirjo Kabupaten Pamekasan Madura [Tesis]. Surabaya: UIN Sunan Ampel; 2016.
51. PERDOSSI. Standar Pelayanan Medik (SPM). 2011. Jakarta: PERDOSSI
52. Lemeshow S, Hosmer D, Klar J, Lwanga S. Adequacy of sample size in health

studies. John Wiley & Sons. 1990.

53. Ismawati, Muis Abdul, Akbar Muhammad, Goysal Yudy, Satrio CK. Hubungan derajat klinis dan gangguan kognitif pada penderita parkinson menggunakan montreal cognitive assessment versi Indonesia [Thesis]. Universitas Hasanuddin. 2014
54. Mandira ALS. [Study of positive influence on quality of life patients with Parkinson's Disease participants Group Lotus]. *Kairós Gerontol.* 2012;15(4):185-99.
55. Muangpaisan W, Mbbs AM. Special Article A Systematic Review of the Worldwide Prevalence and Incidence of Parkinson's Disease. 2011; 94(6):749-55.
56. Jurado-Coronel JC, Cabezas R, Ávila Rodríguez MF, Echeverria V, García-Segura LM, Barreto GE. Sex differences in Parkinson's disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics. *Front Neuroendocrinol.* 2018; 50(2018):18-30.
57. Maryanti Y. Hubungan Polimorfisme Gen Apolipoprotein E dengan Onset, Severitas dan Gangguan Kognitif pada Penyakit Parkinson [Thesis]. *Jurnal Kesehatan Andalas.* Andalas;2014
58. Kim S. The Effects of Socioeconomic Status, Social Support, and Acculturation on the Mental and Physical Health Among Korean American Older Adults in Chicago Metropolitan Area. Louisiana State University, 2002.
61. Amelia D, Syamsuddin T, Ganiem AR. Penilaian Kualitas Hidup Pasien Parkinson Menggunakan PDQ-39 dan Korelasinya dengan Tingkat Keparahan Penyakit. *Neurona.* 2014; 31(3)
62. Tavares DMS, Dias FA, Santos NMF, Haas VJ, Miranzi SC. Factors associated with the quality of life of elderly men. *Rev Esc Enferm USP.* 2013; 47(3): 678-85.
63. Soares GS, Peyré-Tartaruga LA. [Parkinson's disease and physical exercise: a literature review]. *Cien Movimento.* 2011;12(24):69-85. Portuguese.
64. Borges AEA, Mendes LM, Lemos MTM. Physiotherapeutic perception of parkinsonian individuals correlating assessment scales. *Rev Bras Ci Saúde.*

2014;18(3):187-94. Portuguese.

65. Vara AC, Medeiros R, Striebel VLW. Physical therapy in Parkinson's disease. *Rev Neurocienc.* 2012;20(2):266-72. Portuguese.
66. Correia MGS, Paixão AO, Jesus AVF, Silva FS, Messias GMS, Nunes TGM et al. Doença de Parkinson: uma desordem neurodegenerativa. *Cad Grad Ciênc Biol Saúde.* 2013;1(16):57-65.
67. Navarro-Peternella FM, Marcon SS. Living with Parkinson's disease from the perspective of parkinsonians and their relatives. *Rev Gaúcha Enferm.* 2010;31(3):415-22.
68. Rodríguez-Violante M, Cervantes-Arriaga A, Corona T, Martínez-Ramírez D, Morales-Briceño H, Martínez-Martín P. Clinical determinants of health-related quality of life in Mexican patients with Parkinson's disease. *Arch Med Res.* 2013;44(2):110-4.

